

Agnete Svendsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7360269/publications.pdf>

Version: 2024-02-01

41
papers

4,077
citations

331670

21
h-index

377865

34
g-index

44
all docs

44
docs citations

44
times ranked

6366
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50,742 1,430 | 9.1 | 1,430 |
| 2 | Long-term Cultures of Bone Marrow-Derived Human Mesenchymal Stem Cells Frequently Undergo Spontaneous Malignant Transformation. <i>Cancer Research</i> , 2009, 69, 5331-5339. | 0.9 | 590 |
| 3 | CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. <i>International Journal of Cancer</i> , 2008, 122, 761-768. | 5.1 | 508 |
| 4 | Spontaneous Malignant Transformation of Human Mesenchymal Stem Cells Reflects Cross-Contamination: Putting the Research Field on Track - Letter. <i>Cancer Research</i> , 2010, 70, 6393-6396. | 0.9 | 278 |
| 5 | The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. <i>Oncogene</i> , 2008, 27, 5182-5194. | 5.9 | 128 |
| 6 | U251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. <i>Cancer Medicine</i> , 2014, 3, 812-824. | 2.8 | 127 |
| 7 | Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. <i>Acta Neuropathologica</i> , 2011, 122, 495-510. | 7.7 | 125 |
| 8 | Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma. <i>PLoS ONE</i> , 2011, 6, e23062. | 2.5 | 81 |
| 9 | Glioma Cell Populations Grouped by Different Cell Type Markers Drive Brain Tumor Growth. <i>Cancer Research</i> , 2010, 70, 4274-4279. | 0.9 | 77 |
| 10 | AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2020, 15, 973-999. | 1.1 | 66 |
| 11 | Novel Points of Attack for Targeted Cancer Therapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 9-18. | 2.5 | 61 |
| 12 | A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. <i>FASEB Journal</i> , 2008, 22, 3120-3128. | 0.5 | 57 |
| 13 | NK Cells with KIR2DS2 Immunogenotype Have a Functional Activation Advantage To Efficiently Kill Glioblastoma and Prolong Animal Survival. <i>Journal of Immunology</i> , 2014, 193, 6192-6206. | 0.8 | 52 |
| 14 | AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity. <i>Cancer Immunology Research</i> , 2019, 7, 1789-1802. | 3.4 | 52 |
| 15 | Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. <i>Cancer & Metabolism</i> , 2019, 7, 6. | 5.0 | 51 |
| 16 | Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. <i>British Journal of Cancer</i> , 2019, 121, 545-555. | 6.4 | 49 |
| 17 | Role of Hypoxia-Mediated Autophagy in Tumor Cell Death and Survival. <i>Cancers</i> , 2021, 13, 533. | 3.7 | 41 |
| 18 | Hypoxia-driven intratumor heterogeneity and immune evasion. <i>Cancer Letters</i> , 2020, 492, 1-10. | 7.2 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Oxygen-dependent regulation of tumor growth and metastasis in human breast cancer xenografts. PLoS ONE, 2017, 12, e0183254. | 2.5 | 38 |
| 20 | Widespread Dispersion of Adeno-Associated Virus Serotype 1 and Adeno-Associated Virus Serotype 6 Vectors in the Rat Central Nervous System and in Human Glioblastoma Multiforme Xenografts. Human Gene Therapy, 2005, 16, 381-392. | 2.7 | 26 |
| 21 | Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition. Frontiers in Immunology, 2022, 13, 869676. | 4.8 | 24 |
| 22 | Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance. Frontiers in Cell and Developmental Biology, 2018, 6, 41. | 3.7 | 22 |
| 23 | AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer. IScience, 2020, 23, 101649. | 4.1 | 20 |
| 24 | Blocking Aerobic Glycolysis by Targeting Pyruvate Dehydrogenase Kinase in Combination with EGFR TKI and Ionizing Radiation Increases Therapeutic Effect in Non-Small Cell Lung Cancer Cells. Cancers, 2021, 13, 941. | 3.7 | 20 |
| 25 | Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. Journal of Gene Medicine, 2006, 8, 1131-1140. | 2.8 | 19 |
| 26 | Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus. Frontiers in Cellular and Infection Microbiology, 2022, 12, 841447. | 3.9 | 17 |
| 27 | Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.. Journal of Clinical Oncology, 2018, 36, TPS43-TPS43. | 1.6 | 13 |
| 28 | Adaptive mechanisms of resistance to anti-neoplastic agents. MedChemComm, 2017, 8, 53-66. | 3.4 | 12 |
| 29 | Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853. | | 7 |
| 30 | Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models. Frontiers in Oncology, 2022, 12, 818437. | 2.8 | 7 |
| 31 | A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2019, 185, 57-70. | 2.5 | 5 |
| 32 | Abstract 566: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy. , 2016, , . | | 5 |
| 33 | Abstract 626: BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint inhibitor efficacy in lung and mammary adenocarcinoma models. , 2017, , . | | 5 |
| 34 | Induction of alveolar and bronchiolar phenotypes in human lung organoids. Physiological Reports, 2021, 9, e14857. | 1.7 | 4 |
| 35 | Abstract 2928: Bortezomib sensitizes glioblastoma with unmethylated <i>MGMT</i> promoter to temozolomide-chemotherapy through MGMT depletion and abrogated autophagy flux. Cancer Research, 2018, 78, 2928-2928. | 0.9 | 3 |
| 36 | The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance. , 2017, , 351-376. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Abstract 3774: BGB324, a selective small-molecule inhibitor of receptor tyrosine kinase AXL, targets tumor immune suppression and enhances immune checkpoint inhibitor efficacy. , 2018, , . | | 2 |
| 38 | Cancer Immunotherapy 2017 (Paris, France). Progress and challenges. Bulletin Du Cancer, 2018, 105, 537-541. | 1.6 | 1 |
| 39 | Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity. , 2020, , 119-140. | | 1 |
| 40 | Abstract B027: BGB324, a selective small molecule inhibitor of AXL receptor tyrosine kinase, enhances immune checkpoint inhibitor efficacy. , 2016, , . | | 1 |
| 41 | Abstract 1200: AXL targeting enhances lymphocyte-mediated cytotoxicity of lung cancer cells. , 2019, , . | | 0 |